Login to Your Account

MedImmune In-Licenses Clinical Cancer Product From Micromet

By Aaron Lorenzo

Tuesday, June 10, 2003
MedImmune Inc. expanded its oncology pipeline after licensing North American rights to a clinical candidate from a German company, while at the same time taking an equity stake in the privately held firm. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription